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Abstract: When l-dopa use began in the early 1960s for the treatment of Parkinson’s disease, 
nausea and reversible dyskinesias were experienced as continuing side effects. Carbidopa or 
benserazide was added to l-dopa in 1975 solely to control nausea. Subsequent to the increasing 
use of carbidopa has been the recognition of irreversible dyskinesias, which have automatically 
been attributed to l-dopa. The research into the etiology of these phenomena has identified 
the causative agent of the irreversible dyskinesias as carbidopa, not l-dopa. The mechanism 
of action of the carbidopa and benserazide causes irreversible binding and inactivation of 
vitamin B6 throughout the body. The consequences of this action are enormous, interfering with 
over 300 enzyme and protein functions. This has the ability to induce previously undocumented 
profound antihistamine dyskinesias, which have been wrongly attributed to l-dopa and may be 
perceived as irreversible if proper corrective action is not taken.
Keywords: vitamin B6, PLP, irreversible, pyridoxal 5’-phosphate
Introduction
Serotonin, dopamine, norepinephrine, and epinephrine are centrally acting monoamines. 
The immediate amino acid precursor of serotonin is 5-hydroxytryptophan (5-HTP); 
l-3,4-dihydroxyphenylalanine (l-dopa) is the immediate amino acid precursor of 
dopamine. The aromatic l-amino acid decarboxylase (AADC; EC 4.1.1.28) enzyme 
catalyzes the synthesis of serotonin, dopamine, and histamine.1,2
Side effects may position l-dopa as one of the last drugs administered, despite 
the fact that it has the highest efficacy in the treatment of Parkinson’s disease.3 Two 
prominent l-dopa side effects are nausea and dyskinesias. Carbidopa is listed as 
a decarboxylase inhibitor and is sold in the US. It is administered in combination 
with l-dopa to alleviate nausea.4 It irreversibly binds to and permanently deactivates 
pyridoxal 5′-phosphate (PLP) and PLP-dependent enzymes and depletes PLP reserve 
pools.5 The first documentation of novel carbidopa-induced dyskinesias was in 2012.1 
Research into the phenomenon led to the formulation of the hypothesis that if signifi-
cant depletion of histamine induces dyskinesias, then carbidopa is capable of inducing 
dyskinesias, which if not managed properly may be perceived as irreversible.
Benserazide is a decarboxylase inhibitor sold outside of the US. The term 
“benserazide” refers to the drug or its metabolite trihydroxybenzylhydrazine. No 
efficacy claims have been approved by the US Food and Drug Administration (FDA) 
for carbidopa or benserazide.6 Their only indication is management of l-dopa-induced 
nausea, a side effect.4,6 Double-blind studies are used to demonstrate efficacy, but are 
not appropriate for developing comprehensive side-effect profiles. Fatal events, which Clinical Pharmacology: Advances and Applications 2014:6 submit your manuscript | www.dovepress.com
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can occur at a rate of one in 10,000, may not be observed 
during a limited-population and limited-duration study.
Endogenous versus competitive 
inhibition
The endogenous state relating to serotonin and dop-
amine exists when no amino acid precursors are taken, or 
when inadequate or improperly balanced precursors are 
administered. Competitive inhibition is the interaction 
of serotonin and dopamine that may occur in synthesis, 
transport, and metabolism only when adequate and properly 
balanced amounts of serotonin and dopamine amino acid 
precursors are administered simultaneously. Organic cation-
transporter type 2 functional status analysis verifies the 
existence of the serotonin/dopamine competitive inhibition 
state under the apical regulatory supersystem model. When 
competitive inhibition under this system exists, changes to 
either serotonin or dopamine concentrations individually 
will affect both serotonin and dopamine concentrations in 
a predictable manner.1,7–16
Relative nutritional deficiency
A relative nutritional deficiency (RND) exists when opti-
mal nutrient intake cannot meet system needs. Parkinson’s 
disease may induce many RNDs associated with depletions 
of serotonin, dopamine, norepinephrine, epinephrine, thiols 
(homocysteine, l-methionine, S-adenosyl-l-methionine, 
S-adenosyl-homocysteine, cystathione, l-cysteine, and glu-
tathione), l-tyrosine, and l-tryptophan.1,7,17,18–23
l-dopa may induce depletions of serotonin, thiols, 
l-tyrosine, and l-tryptophan, resulting in RNDs (Figure 1).1,7 
Carbidopa may induce depletions of peripheral serotonin, 
dopamine, norepinephrine, and epinephrine, along with 
system-wide depletion of niacin and vitamin B6, resulting 
in multiple system RNDs. Over 300 enzymes and proteins 
require vitamin B6 for normal function.1,7,24–29
Drug/nutrient perspective
A nutrient is any substance that facilitates normal system 
function. A drug is any substance that induces abnormal sys-
tem function. A nutrient may become a drug. A drug may not 
become a nutrient. When the nutrient 5-HTP is administered 
as a single agent, dopamine depletion may occur. If dopamine 
depletion is induced, 5-HTP is no longer functioning as a 
nutrient; it is a drug.1,7–22 When l-dopa is administered as 
a single agent, it may deplete serotonin, and would then be 
considered a drug, not a nutrient.1,7,30–34
l-dopa-induced nausea
The only indication for carbidopa and benserazide is control 
of nausea resulting from improper l-dopa administration. 
The enzyme l-aromatic amino acid decarboxylase (AADC) 
catalyzes the synthesis of serotonin and dopamine by metabo-
lizing 5-HTP and l-dopa, respectively. Through irreversible 
inhibition of AADC, carbidopa or benserazide compromises 
peripheral synthesis of serotonin and dopamine. This drug-
induced inhibition of peripheral metabolism of l-dopa by 
AADC leaves more l-dopa unmetabolized and available 
to freely cross the blood–brain barrier into the central ner-
vous system. As a result, when carbidopa or benserazide is 
administered, lower l-dopa daily intake values are required 
to achieve the same central nervous system results.4,6
It is documented that 5-HTP controls l-dopa-induced 
nausea, utilizing the same basic chemical mechanism as 
carbidopa and benserazide: AADC inhibition. Carbidopa and 
benserazide inhibition is irreversible while 5-HTP inhibi-
tion is reversible. The use of 5-HTP is superior, since under 
proper administration it is a nutrient that does not deplete 
systems or induce abnormal system functions when properly 
administered.1,7,35–37
If the goal of administering 5-HTP for the control of 
l-dopa-induced nausea is to have it function as a nutrient, this 
is not merely a simple substitution. It requires concomitant 
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Figure 1 Administering any of the illustrated components in a dominant manner will facilitate the associated depletion.
Notes: Copyright © 2012. Dove Medical Press. Adapted from Hinz M, Stein A, Uncini T. The discrediting of the monoamine hypothesis. Int J Gen Med. 2012;5:135–142.15
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administration of l-dopa with 5-HTP, along with the “core 
nutrients”: l-tyrosine, a thiol (l-cysteine, glutathione, S-adenosyl 
methionine, or l-methionine), and cofactors (vitamin C, vitamin 
B6, and calcium carbonate). Administration of properly balanced 
core nutrients needs to be guided by organic cation-transporter 
type 2 functional status analysis, in order to achieve a balance 
that does not convert the nutrients into a drug.1,7,37
All l-dopa single-ingredient products were discontin-
ued by the pharmaceutical companies in the US in 1999.38 
Concomitant l-dopa/carbidopa products became the only 
prescription form of l-dopa available. If an indication for 
l-dopa as a single ingredient is identified, it is available 
only as a nutritionally sourced product, such as Mucuna 
cochinchinensis (which is defined by the US Department 
of Agriculture as a synonym for Mucuna pruriens).38,39 Few 
physicians are aware of the existence of this product.
Carbidopa dyskinesias
Abnormal or impaired voluntary movements are dyskinesias.40 
Movement disorders associated with Parkinson’s disease 
include tremors, and other uncoordinated motions. These 
are often seen when there are inadequate levels of l-dopa 
available in the system. For over 50 years, all dyskinesias 
experienced while taking l-dopa or concomitant carbidopa/
l-dopa preparations were described as l-dopa-induced 
dyskinesias.41–48 It is common for dyskinesia studies that 
reference administration of concomitant l-dopa/carbidopa 
to refer to the combination as l-dopa.49
Novel observations reporting a group of 17 Parkinson’s 
disease patients led to identification of carbidopa-induced 
dyskinesias, which had not been documented prior to 2012.1 
These patients had been ingesting prescribed concomitant 
l-dopa/carbidopa preparations for 1–7 years. Their drugs 
were continued as the core nutrients were started. The mean 
daily dosing value of l-dopa/carbidopa was 1,000 mg and 
250 mg, respectively, at the initiation of the core nutrients. 
The mean duration of previous drug treatment was 3 years, 
7 months. Onset of dyskinesias began within the first week 
of treatment when the core nutrients were added. Dyskinesias 
were generally described as facial twitching and head bobbing 
due to peripheral muscle-control problems within the neck 
and upper shoulders. When dyskinesias developed, the l-dopa/
carbidopa was immediately discontinued and the nutrition-
ally sourced l-dopa increased fivefold to compensate for the 
loss of the carbidopa effect on the central nervous system by 
blocking peripheral conversion of l-dopa to dopamine. This 
conversion to higher-dose l-dopa was monitored using the 
previously published pill-stop technique.37 Following this 
protocol, all patients achieved full resolution of dyskinesias 
within 4 days. This led to the hypothesis that the dyskinesias 
that resolved after applying the new protocol had been induced 
by the carbidopa and were not related to the l-dopa. There 
were no refractory dyskinesias experienced.
PLP
Histidine decarboxylase (HDC) and AADC are PLP-dependent 
enzymes that catalyze the metabolism of histidine to 
histamine.50 Each contains an apoprotein core requiring 
irreversible hydrazine–PLP binding for activation. PLP then 
becomes the active site for catalyzing reactions.5 Carbidopa 
and benserazide induce permanent deactivation and irrevers-
ible binding of PLP, PLP-dependent enzymes, and depletion 
of PLP reserve pools.1,24 While PLP freely crosses the blood–
brain barrier,51 carbidopa and benserazide do not.4,6 If car-
bidopa and benserazide deplete peripheral PLP, then central 
PLP is also depleted when the system reaches equilibrium. 
Over 300 enzymes and proteins may be adversely affected 
by this extensive PLP collapse.24
Semantic change and neologisms
Dyskinesias are classified as either reversible or irreversible. 
Between 1960 and 1975, when only the single-ingredient 
l-dopa was available, no l-dopa-induced irreversible dys-
kinesias were documented.52 In 1975, the FDA approved 
the combined formulation of l-dopa with carbidopa for 
Parkinson’s disease treatment. The neologism “l-dopa-
induced irreversible dyskinesias” first appeared in the lit-
erature after 1975.53 A semantic change had occurred: the 
term “l-dopa-induced dyskinesias” was expanded to include 
l-dopa-induced irreversible dyskinesias.
A 1971 article noted: “Transitory adventitious move-
ments are the commonest dose-limiting adverse reaction 
to levodopa in parkinsonian patients. Prompt resolution of 
dyskinetic symptoms usually attends reduction in levodopa 
dosage or the administration of pyridoxine hydrochloride.”54 
A 1999 article noted: “As Parkinson’s disease progresses, the 
dosage and frequency of levodopa needs to be increased to 
maintain control. As a result, most patients develop irrevers-
ible dyskinesias.”55 A 2012 article noted: “The most effective 
pharmacologic treatment for PD, levodopa, has a limited 
period of effectiveness (7–12 years) and is associated with 
irreversible dyskinesias.”56
Antihistamine dyskinesias
To formulate the following observations, Hinz et al treated 
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pruriens-sourced l-dopa, with and without carbidopa. An 
antihistamine is a substance that inhibits the histamine 
agonist, inhibits histamine synthesis, or induces physiologic 
antihistamine effects.57 Antihistamine effects may be exerted 
by 5-HTP (weak), l-dopa (strong), and carbidopa (potentially 
profound). AADC or HDC is exclusively responsible for 
catalyzing histamine synthesis. If 5-HTP induces a reversible 
inhibition of AADC, then a weak antihistamine effect may be 
present.1,16 This is a novel documentation of 5-HTP having a 
potential antihistamine effect.
l-dopa may induce both strong and weak antihistamine 
effects. Dopamine metabolism to epinephrine is without 
biochemical regulation. Synthesis of epinephrine shares 
a direct relationship with dopamine. A strong physiologic 
antihistamine effect is associated with increased epineph-
rine synthesis induced by administration of l-dopa. The 
rapid power of epinephrine to reverse acute life-threatening 
histamine collapse is well known in medicine.57 l-dopa also 
induces a second weaker antihistamine effect through revers-
ible inhibition of AADC.1
Carbidopa and benserazide have the ability to induce a 
previously undocumented profound antihistamine effect. 
These drugs irreversibly bind to and permanently deactivate 
the two PLP-dependent enzymes responsible for histamine 
synthesis: AADC and HDC.5,58,59 This is exacerbated by 
depletion of their PLP substrate and PLP reserve pools.5 
Dyskinesias may be induced by prolonged high-dose antihis-
tamine ingestion or overdose.60–63 If carbidopa is administered 
in high-enough and/or long-enough concentrations to cause 
significant collapse of histamine synthesis, then carbidopa-
induced antihistamine dyskinesias will occur.
Discussion
l-dopa-induced dyskinesias have not been observed or 
documented in the serotonin/dopamine competitive inhibi-
tion state. Prior to 1976 and the introduction of carbidopa, 
there was no documentation of “l-dopa-induced irreversible 
dyskinesias.”52
The molecular weight of PLP is 247.142.63 Carbidopa 
has a molecular weight of 244.244.64 Molecular binding of 
carbidopa to PLP is in a 1:1 ratio. Free adult male PLP is 
placed at 167 mg.65 The PLP that is noncovalently bound to 
about 300 enzymes and proteins represents the PLP reserve 
pool, which is at equilibrium with free PLP.24 The amount of 
PLP bound and unbound system-wide is not agreed upon. 
Assume carbidopa ingestion of 250 mg per day over a 4-year 
period, while ingesting the US-recommended daily allowance 
of about 2 mg of vitamin B6 per day. This reveals a potential 
irreversible carbidopa PLP-induced deficiency of 0.36208 kg 
(0.78 lb). If PLP depletion is great enough, then administra-
tion of 2 mg per day of vitamin B6 will never reverse the 
profound drug-induced PLP RND and the carbidopa-induced 
antihistamine dyskinesias in the patient’s lifetime. The 
observed dyskinesias will be perceived as irreversible.
Effective control of reversible l-dopa-induced dyskinesias 
with PLP was documented in the 15-year precarbidopa era.54 
It is documented that administration of adequate amounts of 
PLP will reverse the AADC and HDC effects from carbidopa 
when it is stopped.66 If discontinuation of carbidopa with 
administration of ample vitamin B6 is effective over time at 
reversing the effects of irreversible binding of carbidopa to 
AADC and HDC as new molecules of these enzymes are 
synthesized, then the approach will be effective in revers-
ing carbidopa-induced antihistamine dyskinesias. The PLP 
reserve pool is much larger than previously realized. It is 
made up of about 300 enzymes and proteins that are nonco-
valently bound to PLP. If the PLP reserve pool is significantly 
greater than anticipated, then adequate reversal of carbidopa 
PLP collapse may take administration of PLP-dosing values 
in excess of those previously associated with restoration of 
PLP collapse. For optimal restoration of PLP collapse, car-
bidopa or benserazide needs to be discontinued.
Conclusion
This paper discusses the mechanism of action whereby 
5-HTP controls l-dopa-induced nausea. It also discusses 
the previously undocumented potential of carbidopa and 
benserazide to induce profound antihistamine dyskinesias 
that are irreversible if ample vitamin B6 replacement is not 
provided.
During the 15 years prior to 1975, when l-dopa was 
prescribed without carbidopa, there was no documenta-
tion of irreversible dyskinesias. After the FDA approval of 
carbidopa/l-dopa, the neologism “l-dopa-induced irrevers-
ible dyskinesias” began to appear in the literature as a seman-
tic change. After carbidopa was approved by the FDA in 1975 
for concomitant administration with l-dopa, all new-onset 
dyskinesias have continued to be wrongly attributed to l-dopa 
alone. Documentation of carbidopa-induced dyskinesias did 
not exist until 2012. Irreversible antihistamine dyskinesias 
are a function of carbidopa’s mechanism of action, which 
causes collapse of histamine synthesis that is exacerbated by 
PLP collapse and PLP reserve-pool depletion.
The possible hesitation of the medical community 
to embrace the nutritional approach by giving up the 
drugs (carbidopa or benserazide) is without foundation. Clinical Pharmacology: Advances and Applications 2014:6 submit your manuscript | www.dovepress.com
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The efficacy of l-dopa without the drugs carbidopa or 
benserazide has been amply documented in double-blind 
studies since 1960. There are no efficacy claims for these 
drugs approved by the FDA. Properly administering the 
nondrug protocol that incorporates the core nutrients defini-
tively controls l-dopa-induced nausea and avoids irreversible 
dyskinesias. No carbidopa or benserazide is utilized in this 
regimen, thereby eliminating the massive vitamin B6 deple-
tion experienced by patients taking the combined l-dopa/
carbidopa formulation. This nutritional approach should 
raise no concern, as all of the ingredients are classified by the 
FDA as being safe enough for over-the-counter sales.
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